Glomerular Disease
Conditions
Keywords
glucocorticoids, primary glomerular disease, sirtuin-1, sclerostin
Brief summary
The aim of the study is to assess the influence of high doses of intravenous corticosteroids on plasma inflammation and bone markers in patients with primary glomerular disease. The study would include 40 patients with chronic kidney disease. The main inclusion criterion is clinical and histopathological diagnosis of primary glomerular disease and urine protein excretion \>2.0 g/24h. The exclusion criteria include secondary glomerular disease, acute kidney injury, acute or chronic inflammation, history of non-compliance.
Detailed description
Glucocorticoids are one of the most widely used classes of drugs to treat inflammatory and autoimmune diseases. They increase formation of osteoclasts and enhance bone resorption thereby increasing risk of bone fractures and osteoporosis. Sirtuin-1(SIRT-1) belongs to family of proteins involved in protection against inflammation and oxidative stress. A role of SIRT-1 in regulation of bone metabolism during high-dose steroid therapy is unknown. The study protocol was approved by the local Bioethics Committee and the study is conducted according to the Declaration of Helsinki. Adult patients with the previous diagnosed primary glomerular disease based on both clinical and renal biopsy findings are included. Plasma concentration of SIRT-1, interleukin-6 (IL-6), fibroblast growth factor 23 (FGF-23), sclerostin, calcium, phosphate, parathormone (PTH) and urine excretion of total protein, albumin, creatinine, calcium and phosphate are measured at baseline. Then the patients receive three intravenous pulses of methylprednisolone of 500 mg followed by oral prednisone 0.8-1.0 mg/kg/24h. The same measurements are repeated 4, 7 and 30 days after starting the steroid treatment.
Interventions
The patients receive intravenous pulses of methylprednisolone 20-30 mg/kg/day for three consecutive days followed by oral prednisone 0.8-1.0 mg/kg/day.
Sponsors
Medical University of Lodz
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* previous diagnosed primary glomerular disease based on both clinical and renal biopsy findings * an estimated glomerular filtration rate ≥15 ml/min/1.73m2 * proteinuria ≥2.0 g/24h
Exclusion criteria
* secondary glomerular disease * acute kidney injury * acute or chronic inflammation * malignancy * uncontrolled hypertension with systolic blood pressure higher than 160 mmHg * symptomatic hypotension * advanced heart failure * history of non-compliance, dementia or depression
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the change of plasma total calcium level after glucocorticoids administration | 30 days |
| the change of plasma phosphate level after glucocorticoids administration | 30 days |
| the change of plasma PTH level after glucocorticoids administration | 30 days |
| the change of urine albumin/creatinine ratio after glucocorticoids administration | 30 days |
| the change of urine total protein/creatinine ratio after glucocorticoids administration | 30 days |
| the change of urine phosphate/creatinine ratio after glucocorticoids administration | 30 days |
| the change of urine calcium/creatinine ratio after glucocorticoids administration | 30 days |
| the change of plasma IL-6 level after glucocorticoids administration | 30 days |
| the change of plasma SIRT-1 level after glucocorticoids administration | 30 days |
| the change of plasma sclerostin level after glucocorticoids administration | 30 days |
| the change of plasma FGF-23 level after glucocorticoids administration | 30 days |
Countries
Poland
Contacts
Primary ContactMichał Nowicki, Prof. MD.
Backup ContactKatarzyna Pęczek, Dr
Outcome results
None listed